Thermo Fisher Scientific Inc. (NYSE:TMO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Thermo Fisher Scientific Inc. (NYSE:TMO) has received an average recommendation of “Moderate Buy” from the twenty-three analysts that are currently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, eighteen have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $616.10.

Several research analysts have weighed in on TMO shares. Morgan Stanley reiterated an “overweight” rating and issued a $620.00 price objective on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. Wells Fargo & Company dropped their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Wednesday, April 8th. Citigroup upped their price objective on shares of Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Finally, Stifel Nicolaus cut their price target on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a report on Friday, April 24th.

Insiders Place Their Bets

In other news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the transaction, the chief executive officer owned 123,925 shares in the company, valued at $63,499,170. This represents a 3.88% decrease in their position. The SEC filing for this sale provides additional information. 0.33% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Montchanin Asset Management LLC acquired a new position in Thermo Fisher Scientific in the 1st quarter valued at $725,000. FinArc Investments Inc. acquired a new position in Thermo Fisher Scientific in the 1st quarter valued at $2,271,000. Western Wealth Management LLC grew its stake in Thermo Fisher Scientific by 31.7% in the 1st quarter. Western Wealth Management LLC now owns 5,918 shares of the medical research company’s stock valued at $2,909,000 after buying an additional 1,424 shares during the last quarter. McIlrath & Eck LLC grew its stake in Thermo Fisher Scientific by 18.9% in the 1st quarter. McIlrath & Eck LLC now owns 353 shares of the medical research company’s stock valued at $174,000 after buying an additional 56 shares during the last quarter. Finally, Paragon Private Wealth Management LLC grew its stake in Thermo Fisher Scientific by 3.5% in the 1st quarter. Paragon Private Wealth Management LLC now owns 759 shares of the medical research company’s stock valued at $373,000 after buying an additional 26 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Down 0.5%

Thermo Fisher Scientific stock opened at $449.43 on Friday. The firm has a market cap of $167.02 billion, a PE ratio of 24.71, a P/E/G ratio of 2.00 and a beta of 0.88. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The firm’s 50 day moving average price is $481.20 and its two-hundred day moving average price is $538.80. Thermo Fisher Scientific has a twelve month low of $385.46 and a twelve month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.19. The firm had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, research analysts predict that Thermo Fisher Scientific will post 24.86 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be issued a dividend of $0.47 per share. The ex-dividend date is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.34%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.